JP2016501515A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501515A5
JP2016501515A5 JP2015539804A JP2015539804A JP2016501515A5 JP 2016501515 A5 JP2016501515 A5 JP 2016501515A5 JP 2015539804 A JP2015539804 A JP 2015539804A JP 2015539804 A JP2015539804 A JP 2015539804A JP 2016501515 A5 JP2016501515 A5 JP 2016501515A5
Authority
JP
Japan
Prior art keywords
composition
animal
stem cell
vector
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015539804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/066651 external-priority patent/WO2014066663A1/en
Publication of JP2016501515A publication Critical patent/JP2016501515A/ja
Publication of JP2016501515A5 publication Critical patent/JP2016501515A5/ja
Priority to JP2018135886A priority Critical patent/JP6975105B2/ja
Pending legal-status Critical Current

Links

JP2015539804A 2012-10-24 2013-10-24 血小板標的化治療 Pending JP2016501515A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018135886A JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
US61/717,951 2012-10-24
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018135886A Division JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Publications (2)

Publication Number Publication Date
JP2016501515A JP2016501515A (ja) 2016-01-21
JP2016501515A5 true JP2016501515A5 (enExample) 2016-11-10

Family

ID=50545271

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015539804A Pending JP2016501515A (ja) 2012-10-24 2013-10-24 血小板標的化治療
JP2018135886A Active JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018135886A Active JP6975105B2 (ja) 2012-10-24 2018-07-19 血小板標的化治療

Country Status (12)

Country Link
US (4) US9982034B2 (enExample)
EP (2) EP2912186B1 (enExample)
JP (2) JP2016501515A (enExample)
KR (1) KR101819803B1 (enExample)
BR (1) BR112015009229B1 (enExample)
CA (1) CA2888982C (enExample)
DK (1) DK2912186T3 (enExample)
ES (1) ES2854754T3 (enExample)
IL (1) IL238417B (enExample)
PL (1) PL2912186T3 (enExample)
WO (1) WO2014066663A1 (enExample)
ZA (1) ZA201502945B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
AU2019205942B2 (en) 2018-01-05 2025-05-15 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
US12403161B2 (en) 2018-06-29 2025-09-02 Stellular Bio, Inc. Compositions for drug delivery and methods of use thereof
CA3115104A1 (en) * 2018-10-05 2020-04-09 University Of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
WO2020186193A1 (en) * 2019-03-13 2020-09-17 Cellphire, Inc. Canine blood platelet preparations
JP7640531B2 (ja) 2019-05-03 2025-03-05 セルフィアー インコーポレイテッド 血液製剤を生産するための材料及び方法
US20210308185A1 (en) 2020-02-04 2021-10-07 Cellphire, Inc. Methods of treating acquired hemophilia with anti-fibrinolytic loaded platelets
US11701388B2 (en) 2019-08-16 2023-07-18 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK0914178T3 (da) 1996-06-18 2003-04-22 Alza Corp Anordning til forøgelse af transdermal afgivelse eller prøveudtagning af et middel
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE234649T1 (de) 1996-12-20 2003-04-15 Alza Corp Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
NZ530131A (en) * 2001-06-15 2005-12-23 Andre C Gene therapy for hemophilia A
WO2003012054A2 (en) * 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
WO2003030934A2 (en) 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
WO2005017160A2 (en) 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
US20060134663A1 (en) 2004-11-03 2006-06-22 Paul Harkin Transcriptome microarray technology and methods of using the same
KR100981092B1 (ko) 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
HUE029454T2 (en) 2009-11-13 2017-03-28 Grifols Therapeutics Inc Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
WO2012119103A2 (en) * 2011-03-02 2012-09-07 Proteonomix, Inc. Compositions and methods for mobilization of stem cells

Similar Documents

Publication Publication Date Title
JP2016501515A5 (enExample)
Abba et al. MicroRNA regulation of epithelial to mesenchymal transition
JP2016500260A5 (enExample)
JP2018522072A5 (enExample)
Roato et al. Cancer stem cells, bone and tumor microenvironment: key players in bone metastases
JP2019514376A5 (enExample)
MX2020005282A (es) Vector para la produccion de particulas aav.
JP2015525065A5 (enExample)
HRP20210057T1 (hr) Presađivanje stem stanica s kombinacijom sredstva koje cilja stem stanice i modulacija imunoregulatorne signalizacije
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2019508051A5 (enExample)
RU2020103811A (ru) Гуманизированные животные по с5 и с3
EA201401319A1 (ru) Способы и композиции рнк-специфической модификации днк-мишении рнк-специфической модуляции транскрипции
EA201590488A1 (ru) Способы модификации клеток-хозяев
JP2016518142A5 (enExample)
JP2012065652A5 (enExample)
JP2013530689A5 (enExample)
JP2017536826A5 (enExample)
EA201690355A1 (ru) Инсектицидные полипептиды с широким спектром активности и их применения
WO2013119371A3 (en) Mini-intronic plasmid vectors
IL269187B2 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
AR125194A2 (es) Una planta transgénica que presenta un rendimiento mejorado y tolerancia al estrés abiótico, y método de obtención de dicha planta
EA201691192A1 (ru) Гены токсинов axmi477, axmi482, axmi486 и axmi525 и способы их применения
Yi et al. Stem-like T cells and niches: Implications in human health and disease
JP2015517520A5 (enExample)